C4 Therapeutics Inc (NASDAQ: CCCC) is -23.89% lower on its value in year-to-date trading and has touched a low of $1.06 and a high of $11.88 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CCCC stock was last observed hovering at around $4.55 in the last trading session, with the day’s loss setting it -0.25%.
Currently trading at $4.30, the stock is -12.95% and -21.47% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.96 million and changing -5.49% at the moment leaves the stock -32.30% off its SMA200. CCCC registered 163.80% gain for a year compared to 6-month gain of -11.16%. The firm has a 50-day simple moving average (SMA 50) of $5.5166 and a 200-day simple moving average (SMA200) of $6.3693.
The stock witnessed a -19.32% loss in the last 1 month and extending the period to 3 months gives it a -28.45%, and is 1.18% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.31% over the week and 9.07% over the month.
C4 Therapeutics Inc (CCCC) has around 145 employees, a market worth around $303.53M and $33.67M in sales. Profit margin for the company is -313.35%. Distance from 52-week low is 305.66% and -63.80% from its 52-week high. The company has generated returns on investments over the last 12 months (-34.69%).
with sales reaching $3.6M over the same period.The EPS is expected to grow by 43.52% this year, but quarterly earnings will post 72.28% year-over-year. Quarterly sales are estimated to grow 10.40% in year-over-year returns.
C4 Therapeutics Inc (CCCC) Top Institutional Holders
161.0 institutions hold shares in C4 Therapeutics Inc (CCCC), with institutional investors hold 103.48% of the company’s shares. The shares outstanding are 70.56M, and float is at 56.67M with Short Float at 13.06%. Institutions hold 91.65% of the Float.
The top institutional shareholder in the company is LYNX1 CAPITAL MANAGEMENT LP with over 6.88 million shares valued at $31.79 million. The investor’s holdings represent 9.9993% of the CCCC Shares outstanding. As of 2024-06-30, the second largest holder is RA CAPITAL MANAGEMENT, L.P. with 4.88 million shares valued at $22.54 million to account for 7.0891 of the shares outstanding. The other top investors are WASATCH ADVISORS LP which holds 4.85 million shares representing 7.0442% and valued at over $22.39 million, while BLACKROCK INC. holds 6.6146 of the shares totaling 4.55 million with a market value of $21.03 million.
C4 Therapeutics Inc (CCCC) Insider Activity
#####
Still, SEC filings show that on Oct 11 ’24, Salter Malcolm (Director) Proposed Sale 8,561 shares at an average price of $5.38 for $46061.0. The insider now directly holds shares of C4 Therapeutics Inc (CCCC).
